Navigation Links
Thoratec Reports 44 Percent Increase in Third Quarter Revenues
Date:10/30/2008

Company Increases Revenue and Earnings Guidance for 2008 Based on

Continuing Adoption of HeartMate II(R)

PLEASANTON, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today said that revenues for the third quarter of 2008 increased 44 percent over revenues in the same period a year ago.

Revenues for the quarter ended September 27, 2008, were $80.8 million versus $56.1 million in the third quarter of 2007. Net income on a GAAP basis in the third quarter of 2008 was $7.2 million, or $0.12 per diluted share, compared with a net loss on a GAAP basis of $1.4 million, or $0.03 per share, in the same period a year ago. Non-GAAP net income, which is described later in this press release, was $10.5 million, or $0.17 per diluted share, compared with non-GAAP net income of $2.5 million, or $0.04 per diluted share, in the third quarter of 2007.

For the first nine months of fiscal 2008, revenues were $227.9 million, a 34 percent increase over revenues of $170.7 million in the first nine months of fiscal 2007. On a GAAP basis, Thoratec reported net income of $16.2 million, or $0.28 per diluted share, versus a net loss of $430,000, or $0.01 per share, in the same period a year ago. Non-GAAP net income for the first nine months of fiscal 2008 was $27.1 million, or $0.45 per diluted share, compared with non-GAAP net income of $12.0 million, or $0.22 per diluted share, in the first nine months of fiscal 2007.

"As was the case last quarter, our strong financial performance was driven by the continued adoption of the HeartMate II LVAS (Left Ventricular Assist System
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
2. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
3. Thoratec Presentation at JP Morgan Conference to be Webcast
4. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
5. Thoratec Presentation at Bear Stearns Conference To Be Webcast
6. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
10. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
11. United Therapeutics Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... consumer of benzene. Benzene is processed to get such derivatives as ethylbenzene, a ... derivatives are principally used within the automotive industry for the production of tyres ...
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Aethlon Medical, Inc. ... biofiltration devices to treat life-threatening diseases, today announced that ... conference call and webcast on Thursday, August 13, 2015 ... and webcast will follow the release of fiscal 2016 ... will be available approximately two hours after the call ...
(Date:8/3/2015)... YORK , August 3, 2015 ... Market Study on 3D Cell Culture: Asia ... by Persistence Market Research, the global 3D cell culture market was ... expected to expand at a CAGR of 29.1% to ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
Breaking Biology Technology:World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... a biotechnology company developing novel regenerative therapies to ... $3.4 million Series A investment led by North ... JumpStart Inc., Fletcher Spaght Investments, Glengary LLC, Ohio ... Gen Ltd. and a significant number of individuals. ...
... A novel microscopy method at the Department of ... the reactions that limit widespread deployment of fuel cell ... electrochemical strain microscopy that enables them to examine the ... which may reveal ways to redesign or cut the ...
... 15, 2011 A new post-hoc sub-analysis of an ... – those identified as the "core clinical cohort" population ... aspirin) was associated with a 26 percent relative risk ... myocardial infarction or stroke, compared to treatment with clopidogrel ...
Cached Biology Technology:SironRX Therapeutics Raises $3.4 Million Series A 2ORNL microscopy generates new view of fuel cells 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, ... expected revenues in 2015 that relate to sales of FPC1025 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... in China and we are proud that ... for Axon , its first ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... Cambridge and Boston, MA. Wed. July 4, 2012 One ... after treatment. In the case of many forms of cancer, ... eradicate cancer cells in the lab, but often produce only ... in the field of cancer research has been and remains: ...
... new type of scholarly articles, which are rapidly gaining ... publications that describe data sets and provide an opportunity ... citation and re-use of the published data. Data Papers ... among the international organization Global Biodiversity Information Facilities ...
... coast of North America is reaching the level of the ... by a researcher at the University of British Columbia. ... Bulletin , examined stomach contents of beached northern fulmars on ... Washington and Oregon, U.S.A. "Like the canary in the ...
Cached Biology News:Tumor microenvironment helps skin cancer cells resist drug treatment 2Tumor microenvironment helps skin cancer cells resist drug treatment 3Tumor microenvironment helps skin cancer cells resist drug treatment 4A new type of data papers designed to publish online interactive keys identifying biodiversity 2Seabirds study shows plastic pollution reaching surprising levels off coast of Pacific Northwest 2
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
...
... series of Class II Biological Safety ... certification to the world's highest safety ... the cabinets cannot be adjusted out ... low noise and arm rest ensure ...
... Thermo's orbital shaker stands both ... more ergonomic height, and help ... from welded tubular steel, these ... support the weight and minimize ...
Biology Products: